Trial site
Highlands Oncology Group, PA
Springdale, Arkansas 72762, United StatesNot linked to an institution yet
- 13running trials
- 1closed trial
The trials here
What the 14 trials at this site are about, from their registry records.
- Phase
- Phase 35 trials
- Phase 13 trials
- Phase 1/23 trials
- Phase 23 trials
- Status
- Recruiting8 trials
- Active, not recruiting5 trials
- Completed1 trial
- Lead sponsor
- Pfizer10 trials
- Seagen, a wholly owned subsidiary of Pfizer1 trial
- Shanghai Henlius Biotech1 trial
- Stemline Therapeutics, Inc.1 trial
- University of Arkansas1 trial
Running trials
Recruiting
A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
NCT07477587· Phase 1· Shanghai Henlius Biotech· Source
Contact: Yinping Zhong
Recruiting
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
NCT07421700· Phase 1/2· Pfizer· Source
Recruiting
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
NCT07227415· Phase 1/2· Pfizer· Source
Recruiting
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
NCT07227298· Phase 1/2· Pfizer· Source
Recruiting
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT07144280· Phase 3· Pfizer· Source
Recruiting
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
NCT07028853· Phase 3· Pfizer· Source
Recruiting
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965· Phase 3· Pfizer· Source
Active, not recruiting
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT06760637· Phase 3· Pfizer· Source
Recruiting
Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence
NCT05952934· Phase 2· University of Arkansas· Source
Contact: Jennifer Worth
Active, not recruiting
ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study
NCT05596409· Phase 2· Stemline Therapeutics, Inc.· Source
Active, not recruiting
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
NCT05538130· Phase 1· Pfizer· Source
Active, not recruiting
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
NCT05355701· Phase 1· Pfizer· Source
Active, not recruiting
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
NCT05059522· Phase 3· Pfizer· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error